NCT05140148View on ClinicalTrials.gov

Promoting Recovery After STroke With Amantadine

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

February 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Stroke, IschemicStroke Hemorrhagic
Interventions
DRUG

Amantadine

Amantadine is a antiviral drug and dopamine promoter that is currently approved by the FDA for the treatment of influenza A and Parkinson's Disease

DRUG

Placebo

placebo pills

Trial Locations (1)

19104

RECRUITING

The Hospital of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

University of Pennsylvania

OTHER